Latest News

FDA Approves Merck's 21-Valent Pneumococcal Vaccine for Adults 50 Years of Age and Older: A First and Long-Awaited
FDA Approves Merck's 21-Valent Pneumococcal Vaccine for Adults 50 Years of Age and Older: A First and Long-Awaited

June 18th 2024

Capvaxive is the only pneumococcal vaccine formulated specifically to protect adults 50 years and older from IPD and elicited robust immune responses in both vaccine-naïve and vaccine-experienced adults.

FDA Approves First mRNA Vaccine Against RSV for Adults Aged ≥60 Years: Daily Dose / image credit: ©New Africa/AdobeStock
FDA Approves First mRNA Vaccine Against RSV for Adults Aged ≥60 Years: Daily Dose

June 7th 2024

FDA Approves Moderna's mRESVIA, First mRNA Vaccine Against RSV, for Adults Aged ≥60 Years / image credit FDA approval ©Waldenmarus/stock.adobe.com
FDA Approves Moderna's mRESVIA, First mRNA Vaccine Against RSV, for Adults Aged ≥60 Years

June 3rd 2024

FDA Decision on Dupilumab for COPD Pushed Back to September 2024
FDA Decision on Dupilumab for COPD Pushed Back to September 2024

May 31st 2024

Latest CME Events & Activities

Respiratory Syncytial Virus: Understanding the Infection Burden and Anticipating the Impact of Vaccines

View More

Engaging the Multidisciplinary Care Team to Optimize Care of Patients With EGFR Mutation–Positive NSCLC: A Lung Cancer Tumor Board

View More

Expanding the Armamentarium of Actionable Mutations in NSCLC: Uncovering the Potential of CEACAM5 as a Therapeutic Target

View More

Rapid post- ASCO Archive – How Do Emerging Data for ICIs, BiTEs, ADCs, and Targeted Strategies Address Unmet Needs in the Therapeutic Continuum for SCLC?

View More

Rapid Post-ASCO Archive: Top 10 Oncogenic Drivers in NSCLC for 2024—Where Are We and Where Are We Going?

View More

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

View More

Rapid Post-ASCO Archive – DLL3 as a Therapeutic Target in SCLC and Beyond: Rationale, Recent Data and Potential for Transformations in Care with T-Cell Engagers

View More

25th Annual International Lung Cancer Congress®

July 25-27, 2024

Register Now!

24th Annual International Lung Cancer Congress®

View More

Engaging the Multidisciplinary Care Team to Optimize Care of Patients With EGFR Mutation-Positive NSCLC: A Lung Cancer Tumor Board

View More

Pathology Implications for CEACAM5 as a Therapeutic Target in Advanced NSCLC

View More

Medical Crossfire®: What Are Effective Strategies for Onco-Nurses to Improve Outcomes in Patients with Small Cell Lung Cancer?

View More

Advances In™: Aligning Pathology and Oncology Efforts in the Community to Improve NSCLC Care

View More

Community Practice Connections: 7th Annual School of Nursing Oncology™

View More

6th Annual Precision Medicine Symposium: An Illustrated Tumor Board

October 18-19, 2024

Register Now!

Virtual Show Me the Data™: How HER2, HER3, and TROP2 Targeted Strategies Will Impact Evolving Paradigms in NSCLC

View More

6th Annual Advanced Practice Collaborative

View More

Community Practice Connections™: 24th Annual International Lung Cancer Congress®

View More

42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®

November 13-15, 2024

Register Now!

19th Annual New York Lung Cancers Symposium®

November 16, 2024

Register Now!

Let’s Get “Real”: Alpha-1 Antitrypsin Deficiency—Case-Based Perspectives on Managing Associated Emphysema

View More

Shaping the Management of COPD with Biologic Therapy

View More

Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes

View More

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

EGPA: Highlighting the Patient Journey to Improve the Differential Diagnosis and Accelerate the Initiation of Guideline-Based Care

View More

Identifying Actionable Biomarkers in NSCLC: Real World Case Discussions on Applications of Testing in the Treatment Planning Process

View More

How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities

View More

Lung Cancer Tumor Board®: Enhancing Multidisciplinary Communication to Optimize Immunotherapy in Stage I-III NSCLC

View More

Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!

View More

Matching Treatment to Patient with EGFR-Mutant Lung Cancer: Mutation Subtypes, Co-Mutations, and Managing Resistance

View More

More News

© 2024 MJH Life Sciences

All rights reserved.